Shots:

• The P-IV HER-MES study evaluates the tolerability & efficacy of Aimovig (70/140mg) vs topiramate in 777 patients with episodic or chronic migraine (=4 migraine days/month) prior to not being treated with migraine prevention treatment or previously failed up to 3 previous therapies. The study was conducted in collaboration with Novartis at 82 study sites in Germany
• The results showed a lower discontinuation rate due to AEs (10.6% vs 38.9%). Additionally, a greater proportion of patients achieved at least a 50% reduction from baseline in their MMDs (55.4% vs 31.2%)
• Aimovig is the 1st FDA-approved migraine preventive treatment that targets CGRP receptors associated with migraine

  Ref: PR Newswire | Image: Amgen